Recurrence of prostate cancer is suspected when an increase in the prostate-specific antigen level is detected after radical treatment; the recurrence could be local relapse, distant relapse, or both. Differentiation between the two patterns of relapse is critical for choosing the proper treatment strategy. Choline PET/CT could be of help in discriminating patients with local, lymph node, and bone recurrences, thus having an impact on patient management.
The available data regarding the diagnostic performance of 11 Ccholine PET/CT in detecting local recurrence in patients with BR are limited and controversial. Reske et al. evaluated the role of 11 C-choline PET/CT in 36 patients with biopsy-proven low-volume local recurrence after radical prostatectomy (RP), reporting a sensitivity and a specificity of 73% and 88%, respectively (5). Souvatzoglou et al. found 11 C-choline uptake in the prostatic bed in 7 of 37 patients (19%) who had PSA failure after RP and were candidates for salvage radiotherapy (RT) of the prostatic fossa (6) . These data were substantially confirmed by Kitajima et al., who found a sensitivity of 54% and a specificity of 92% for 11 C-choline PET/CT in the detection of local relapse in 87 patients after RP (7) .
Lymph Node Recurrence
Few prospective studies investigating the accuracy of 11 C-choline PET/CT in detecting lymph node metastases in patients with BR and having histopathology as a reference standard are currently available. One of the first studies was performed by Scattoni et al. (8) . Using a per-lesion analysis, they found sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of 64%, 90%, 86%, 72%, and 77%, respectively, for 11 C-choline PET/CT (8) . Similar results were reported by Schilling et al. (9) and Rinnab et al. (10) , supporting the use of 11 C-choline PET/CT in patients with BR and suspected lymph node metastases. Kitajima et al. compared 11 C-choline PET/CT results with multiparametric MRI results in 115 patients with BR after RP (7) . They reported patientbased sensitivity, specificity, and accuracy of 90%, 100%, and 93%, respectively, for 11 C-choline PET/CT in the detection of lymph node recurrence; with MRI, sensitivity, specificity, and accuracy for pelvic nodal involvement were 64%, 85%, and 70%, respectively (7).
Bone Metastases 11 C-choline PET/CT is an imaging modality that can be useful in detecting bone metastases. Fuccio et al. compared 11 C-choline PET/CT and bone scanning in 25 patients who had BR and only 1 bone lesion on bone scanning (11). 11 C-choline PET/CT detected multiple sites of relapse in 44% of the patients, with a sensitivity and a specificity of 86% and 100%, respectively (11) . A direct comparison of 11 C-choline PET/CT and bone scanning was performed by Picchio et al. in 78 patients with PSA progression after primary treatment (12) . They found a lower sensitivity for 11 C-choline PET/CT than for bone scanning (89% vs. 100%) but a higher specificity (98% vs. 75%) (12) . Ceci et al. used 11 C-choline PET/CT to study 304 bone lesions (184 osteoblastic, 99 osteolytic, and 21 bone marrow lesions) in 140 patients during BR (13) . They found a significant difference in the SUV max between osteoblastic lesions (lower values) and osteolytic lesions (higher values) (13) .
INFLUENCE OF PSA ON RATE OF DETECTION BY 11 C-CHOLINE PET/CT
Various studies have investigated the diagnostic accuracy of 11 C-choline PET/CT for detecting PCa recurrence and have reported different values for sensitivity and specificity (5, (7) (8) (9) 11, 12, 14) . These variations could be attributed to the heterogeneity of patient populations in terms of inclusion criteria (i.e., PSA level, staging, and presence or absence of androgen deprivation therapy [ADT] ). In addition to the largely documented influence of serum PSA measurement on the rate of detection of PCa recurrence by 11 C-choline PET/CT (10, 14, 15) , several studies have reported that PSA kinetics, including PSA doubling time (PSAdt) and PSA velocity (PSAvel), are strong predictors for positive PET scan results.
Castellucci et al. investigated 190 patients with BR, subdividing the population into different groups according to trigger PSA levels, and identified an optimal PSA level of 2.43 ng/mL for detecting recurrent disease with a sensitivity and a specificity of 73% and 69%, respectively (16) . The same group found that 11 C-choline PET/CT results were positive in 28% of 102 patients who experienced only slight increases in PSA levels (,1.5 ng/mL), with 7 patients having local recurrence, 13 having bone metastases, and 9 having lymph node relapse (17) .
Using a larger cohort of patients, Giovacchini et al. found a patientbased sensitivity of 85%, specificity of 93%, and accuracy of 89% for 11 C-choline PET/CT in the detection of recurrent disease in 358 patients previously treated for PCa (18) . As expected, the rate of positive scan results increased with increasing PSA levels (19% for PSA levels of 0.23-1 ng/mL, 46% for PSA levels of 1-3 ng/mL, and 82% for PSA levels of .3 ng/mL); the optimal PSA level was identified as 1.4 ng/mL (sensitivity, 73%; specificity, 72%) (18) . Using a cohort of 170 patients with BR of PCa, the same group demonstrated that-like PSA-PSAdt is an independent predictor for 11 C-choline PET/CT (19).
Rybalov et al. evaluated 185 patients with BR to assess the impact of PSA levels and PSA kinetics on rates of detection by 11 C-choline PET/CT (20) . A significant difference in the area under curve was observed between total PSA (0.721; P , 0.001) and PSAvel (0.730; P , 0.001) (20) . Moreover, detection rates were less than 50% for PSA levels of less than 2 ng/mL or PSAvel of less than 1 ng/mL/y (20). Bertagna et al. suggested that the highest accuracy for patients with BR and treated only with RT is reached when 11 Ccholine PET/CT is performed above a cutoff value for PSA of 2.0 ng/mL (21). Mamede et al. evaluated the role of 11 C-choline in 71 patients who had BR after RP and a PSA level of less than 0.5 ng/mL and found true-positive findings in 21.1% of the patients (22) . The mean 6 SD PSA level, PSAdt, and PSAvel for patients with 11 Ccholine PET/CT-positive results were 0.37 6 0.1 ng/mL, 3.4 6 2.1 mo, and 0.05 6 0.1 ng/mL/y, respectively (22) . Interestingly, only PSAdt and the ongoing hormonal treatment were statistically significant in the prediction of positive PET/CT scan results in a multivariate analysis (22) . Mitchell et al. evaluated the performance of 11 C-choline PET/CT in 176 patients with BR after treatment and found sensitivity, specificity, PPV, and NPV of 93%, 76%, 91%, and 81%, respectively (23) . Moreover, the optimal PSA level for lesion detection was shown to be 2.0 ng/mL, and a multivariate analysis demonstrated that PSA (hazard ratio, 1.37; P 5 0.04) and clinical stage at initial diagnosis (hazard ratio, 5.19; P 5 0.0035) were significant predictors of positive 11 C-choline PET/CT scan results (23) . In a recent metaanalysis, Fanti et al. reported a 11 Ccholine PET/CT rate of detection of PCa at any site of relapse of 62% (95% confidence interval, 53%-71%), a pooled sensitivity of 89% (95% confidence interval, 83%-93%), and a pooled specificity of 87% (95% confidence interval, 71%-95%); these results were similar to previously reported results (24) .
F-CHOLINE PET/CT IN RECURRENT PCA Local Recurrence
As for 11 C-choline PET/CT, limited diagnostic accuracy of 18 F-choline PET/CT in detecting local recurrence has been reported. Using 18 F-choline and 11 C-acetate PET/CT in a small cohort of 22 patients referred for salvage or adjuvant RT, Vees et al. observed a rate of detection of 55% for PSA levels of less than 1 ng/mL (25) . In that study, MRI results were positive in 83% of the patients; this finding suggested that MRI may be more useful than PET/CT in patients with a low likelihood of distant metastases because the sensitivity and specificity of PET/CT were too low to justify its use as a standard diagnostic imaging modality for identifying early relapse (25 PET/CT performance in patients with PCa recurrence (26) . The population was subdivided into 2 groups: group A, including 28 patients with lesion sizes of 5-7.2 mm and a reduction in PSA levels after RT, and group B, including 56 patients with lesion sizes of 7.6-19.4 mm. In group A, the sensitivity, specificity, PPV, and accuracy of PET/CT in identifying local recurrence were 62%, 50%, 88%, and 60%, respectively (26) . The diagnostic performance of MRI was better, given that the sensitivity, specificity, PPV, and accuracy were 92%, 75%, 96%, and 89%, respectively (26) . Also, in group B, the performance of PET/CT was poorer than that of MRI, given that the sensitivity, specificity, PPV, and accuracy of PET/CT were 92%, 33%, 98%, and 91%, respectively, whereas those of MRI were 94%, 100%, 100%, and 94%, respectively (26) .
Lymph Node Recurrence
Few of the studies currently available have assessed the role of 18 F-choline PET/CT in detecting recurrence in the lymph nodes. Husarik et al. studied 111 patients who had PCa and underwent 18 F-choline PET/CT; 68 of these patients underwent this scan for the purpose of restaging (27) . Local recurrence was correctly identified in 36 of 68 patients (27) . Twenty-three patients had 18 F-choline lymph node uptake, and in 20 of these 23 patients, lymph nodes were surgically removed (27) . Histopathology confirmed metastases in all lymph nodes but also revealed 2 additional metastases that were not detected by 18 F-choline PET/CT (27) . Tilki et al. used 18 F-choline PET/CT to study 56 PCa patients who had BR after RP and who subsequently underwent bilateral pelvic or retroperitoneal lymphadenectomy on the basis of positive 18 F-choline PET/CT findings (28) . Of 1,149 lymph nodes that were removed and histologically evaluated, 282 (24.5%) harbored metastases (28) . A lesion-based analysis yielded 18 F-choline PET/CT sensitivity, specificity, PPV, and NPV of 39.7%, 95.8%, 75.7%, and 83.0%, respectively (28) .
Bone Metastases
Regarding the diagnostic performance of 18 F-choline PET/CT in detecting bone metastases, Beheshti et al. compared the uptake of 18 F-fluorocholine in bone metastases in 70 patients before and after treatment for PCa with morphologic changes identified on CT (29) . Overall sensitivity, specificity, and accuracy were 79%, 97%, and 84%, respectively, with lytic lesions showing higher metabolism than sclerotic lesions (29) . The same group compared the potential value of 18 F-choline with that of 18 F-fluoride in detecting bone metastases in a cohort of 38 patients that included 21 patients with BR and suspected bone metastases (30) . They reported sensitivity, specificity, and accuracy of 74%, 99%, and 85%, respectively, for 18 F-choline and 81%, 93%, and 86%, respectively, for 18 As for 11 C-choline, the role of 18 F-choline has been largely investigated in the setting of BR of PCa, and it appears that the sensitivity of this imaging modality is influenced by PSA levels and PSA kinetics. Cimitan et al. included 100 patients with BR after primary treatment for PCa in a study assessing the role of this imaging modality in detecting recurrent PCa (33) . Interestingly, 89% of negative PET/CT scans were obtained in patients with serum PSA levels of less than 4 ng/mL and 87% of such scans were obtained in patients with a Gleason score of less than 8 (33). Pelosi et al. reported a sensitivity of 42.9% in detecting PCa lesions in 56 patients with BR after RP; detection rates increased with increasing PSA levels (20% at PSA levels of ,1 ng/mL, 44% at PSA levels of 1-5 ng/mL, and 82% at PSA levels of .5 ng/mL) (34) .
More recent studies reported a better rate of detection by 18 Fcholine PET/CT in PCa restaging. Chondrogiannis et al. reported a positive detection rate of 80.4% in 46 patients with a suspected relapse after RT (35) . Similarly to Pelosi et al. (34) , this group also found increasing detection rates with increasing trigger PSA levels and reported that the detection rate was not influenced by ADT (35) . Similar results were reported by Beheshti et al. in a population of 250 patients with BR; 18 F-choline PET/CT detected malignant lesions in 185 of the 250 patients (74%) (36) . The sensitivities of 18 F-choline PET/CT increased with increasing trigger PSA levels (77.5%, 80.7%, 85.2%, and 92.8% at trigger PSA levels of .0.5, 1.0, 2.0, and 4.0 ng/mL, respectively) and were higher in patients who were receiving ongoing ADT (85%) than in patients who were not (59.5%) (P 5 0.001) (36) . Other investigators have suggested that ADT may be withheld before examination to reduce the risk of false-negative scans and thereby to increase the rate of detection by 18 F-choline PET/CT (5, 10, 27, 37) .
Using a cohort of 82 patients with BR after RP, Graute et al. reported a detection rate of 62% and observed that the median PSA level was significantly higher in patients with PET-positive results than in those with PET-negative results (4.3 vs. 1.0 ng/mL; P , 0.01) (38) . An optimal PSA threshold of 1.74 ng/mL for detecting recurrent disease was demonstrated by receiver operating characteristic curve analysis (area under the curve, 0.818; 82% sensitivity; 74% specificity) (38) . Moreover, significant differences between patients with PET-positive results and those with PETnegative results were found for median PSAvel (6.4 vs. 1.1 ng/mL/y; P , 0.01) and PSA progression (5.0 vs. 0.3 ng/mL/y; P , 0.01), with corresponding optimal thresholds of 1.27 and 1.28 ng/mL/y, respectively (38) .
Similar results were reported by Schillaci et al., who found that the rate of detection by 18 F-choline imaging was closely related to PSA levels and PSA kinetics (39) . In particular, this group recommended 18 F-choline PET/CT in patients with PSA levels of greater than 2 ng/mL, PSAdt of less than or equal to 6 mo, and PSAvel of greater than 2 ng/mL/y (39). Marzola et al. investigated 233 patients with BR after RP and a high risk for relapse and reported an overall rate of detection by 18 F-choline PET/CT of 54%; this rate increased significantly with increasing PSA levels (P , 0.001) (40) . Interestingly, patients with positive PET/CT scan results had faster PSA kinetics (mean PSAdt, 6 mo; mean PSAvel, 9.3 ng/mL/y) than patients with negative PET scan results (mean PSAdt, 15.4 mo; mean PSAvel, 0.9 ng/mL/y) (40).
Detti et al. evaluated the potential of 18 F-choline in 129 patients who underwent PET/CT for the purpose of restaging (41) . They observed sensitivity and specificity of 100% and 56.9%, respectively, and found that PSA levels of greater than or equal to 1 ng/mL at the time of restaging were statistically significant predictive factors for PET-positive results, through either univariate analysis (P , 0.0001) or multivariate analysis (P , 0.0001) (41) .
Recently, Chiaravalloti et al. investigated the performance of 18 F-choline in detecting recurrent PCa and its relationship with PSAdt and PSAvel in 79 patients who were treated with RP and had low PSA levels (,2 ng/mL) (42) . They found significant differences in PSAvel and PSAdt between patients with positive 18 F-PET/CT scan results and those with negative 18 F-PET/CT scan results (42) . Using thresholds of 6 mo for PSAdt and 1 ng/mL/y for PSAvel, they found detection rates of 65% for PSAdt of less than or equal to 6 mo and 67% for PSAvel of greater than 1 ng/mL/y (42). These results suggested that 18 F-choline PET/CT could be considered for the evaluation of patients with BR of PCa and with low PSA levels and that fast PSA kinetics could be useful in the selection of patients (42) .
CONCLUSION
In patients with BR of PCa, either 11 C-choline PET/CT or 18 Fcholine PET/CT has good accuracy in detecting lymph node and distant metastases, with the main advantage of being a single wholebody examination. However, limited accuracy regarding its role in detecting local recurrence is still being reported. The influence of PSA levels and PSA kinetics on the rate of detection by choline PET/CT should always be considered when this examination is performed in order to obtain a better patient selection.
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